This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mattiuzzi, G. N. Articles by Kantarjian, H. M. Search for Related Content PubMed PubMed Citation Articles by Mattiuzzi, G. N. Articles by Kantarjian, H. M.

Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate

Departments of Leukemia [G. N. M., J. E. C., M. B. R., J. S., F. J. G., S. V., A. F., H. M. K.], Bioimmunotherapy [M. T.], Infectious Diseases [D. K., I. R.], and Hemtopathology [J. R.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Purpose: Infection with Varicella-Zoster virus (VZV) is an exceptionally rare complication of chronic myelogenous leukemia (CML) without stem cell transplantation. We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy.

Patients and Methods: From July 1998 until February 2002, 771 patients were included in 11 imatinib mesylate studies for all CML phases in the Departments of Leukemia and Bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center. Sixteen patients developed VZV infection. Charts and follow-up information of were reviewed and analyzed.

Results: Sixteen patients (2%) developed a VZV infection [15 episodes of herpes zoster (HZ), 1 varicella]. The baseline characteristics of the 16 patients with infection do not differ significantly from those who did not develop VZV infection, except for time from diagnosis of CML to imatinib (median: 55 versus 25 months, P = 0.0056) and the number of prior therapies (3 versus 1, P < 0.001). All patients received therapy with antiviral agents with good response. Six patients developed postherpetic neuralgia.

Conclusions: Our results suggest that imatinib therapy in CML is associated with low incidence of HZ infection. VZV infection is more frequent with longer duration of CML disease and with prior therapy, does not disseminate, responds well to therapy, and does not mandate a recommendation for HZ prophylaxis in such patients.

This article has been cited by other articles:

				D. A. Dorr, R. Burdon, D. P. West, J. Lagman, C. Georgopoulos, S. M. Belknap, J. M. McKoy, B. Djulbegovic, B. J. Edwards, S. A. Weitzman, et al. Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate Clin. Cancer Res., June 1, 2009; 15(11): 3850 - 3855. [Abstract] [Full Text] [PDF]

				J. M. A. Daniels, A. Vonk-Noordegraaf, J. J. W. M. Janssen, P. E. Postmus, and R. van Altena Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia Eur. Respir. J., March 1, 2009; 33(3): 670 - 672. [Abstract] [Full Text] [PDF]

				L. Senn, T. Kovacsovics, P. E. Tarr, and P. Meylan Peritoneal Tuberculosis After Imatinib Therapy Arch Intern Med, February 9, 2009; 169(3): 312 - 313. [Full Text] [PDF]

				M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations Ann. Onc., October 1, 2008; 19(10): 1713 - 1719. [Abstract] [Full Text] [PDF]

				Y. Huang, E. O. Comiskey, R. S. Dupree, S. Li, A. J. Koleske, and J. K. Burkhardt The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse Blood, July 1, 2008; 112(1): 111 - 119. [Abstract] [Full Text] [PDF]

				J. J. Gu, N. Zhang, Y.-W. He, A. J. Koleske, and A. M. Pendergast Defective T Cell Development and Function in the Absence of Abelson Kinases J. Immunol., December 1, 2007; 179(11): 7334 - 7343. [Abstract] [Full Text] [PDF]

				P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo J. Immunol., February 15, 2007; 178(4): 2028 - 2037. [Abstract] [Full Text] [PDF]

				B. Gao, S.-M. Lee, and D. Fang The Tyrosine Kinase c-Abl Protects c-Jun from Ubiquitination-mediated Degradation in T Cells J. Biol. Chem., October 6, 2006; 281(40): 29711 - 29718. [Abstract] [Full Text] [PDF]

				J. C. Wade Viral Infections in Patients with Hematological Malignancies Hematology, January 1, 2006; 2006(1): 368 - 374. [Abstract] [Full Text] [PDF]

				R. Seggewiss, K. Lore, E. Greiner, M. K. Magnusson, D. A. Price, D. C. Douek, C. E. Dunbar, and A. Wiestner Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner Blood, March 15, 2005; 105(6): 2473 - 2479. [Abstract] [Full Text] [PDF]

				G. Andrei, R. Sienaert, C. McGuigan, E. D. Clercq, J. Balzarini, and R. Snoeck Susceptibilities of Several Clinical Varicella-Zoster Virus (VZV) Isolates and Drug-Resistant VZV Strains to Bicyclic Furano Pyrimidine Nucleosides Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1081 - 1086. [Abstract] [Full Text] [PDF]

				S. Appel, A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, and P. Brossart Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-{kappa}B and Akt Signaling Pathways Clin. Cancer Res., March 1, 2005; 11(5): 1928 - 1940. [Abstract] [Full Text] [PDF]

				R. T. Maziarz Imatinib mesylate: a novel immune suppressive agent? Blood, August 15, 2004; 104(4): 914 - 915. [Full Text] [PDF]

				A. B. Dietz, L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow, and S. Vuk-Pavlovic Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo Blood, August 15, 2004; 104(4): 1094 - 1099. [Abstract] [Full Text] [PDF]